191 related articles for article (PubMed ID: 30575283)
1. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.
Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B
J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283
[TBL] [Abstract][Full Text] [Related]
2. Combined endogenous MR biomarkers to assess changes in tumor oxygenation induced by an allosteric effector of hemoglobin.
Cao-Pham TT; Tran-Ly-Binh A; Heyerick A; Fillée C; Joudiou N; Gallez B; Jordan BF
NMR Biomed; 2020 Feb; 33(2):e4181. PubMed ID: 31762121
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells.
Oknińska M; El-Hafny-Rahbi B; Paterek A; Mackiewicz U; Crola-Da Silva C; Brodaczewska K; Mączewski M; Kieda C
J Cell Mol Med; 2020 Feb; 24(3):2272-2283. PubMed ID: 31957267
[TBL] [Abstract][Full Text] [Related]
4. Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumors.
Krzykawska-Serda M; Szczygieł D; Gaweł S; Drzał A; Szczygieł M; Kmieć MM; Mackiewicz A; Kieda C; Elas M
PLoS One; 2023; 18(5):e0285318. PubMed ID: 37167239
[TBL] [Abstract][Full Text] [Related]
5. Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response.
Grgic I; Tschanz F; Borgeaud N; Gupta A; Clavien PA; Guckenberger M; Graf R; Pruschy M
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1222-1233. PubMed ID: 33587991
[TBL] [Abstract][Full Text] [Related]
6. Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Limani P; Linecker M; Kachaylo E; Tschuor C; Kron P; Schlegel A; Ungethuem U; Jang JH; Georgiopoulou S; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA
Clin Cancer Res; 2016 Dec; 22(23):5887-5897. PubMed ID: 27489288
[TBL] [Abstract][Full Text] [Related]
7. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.
Kieda C; Greferath R; Crola da Silva C; Fylaktakidou KC; Lehn JM; Nicolau C
Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15576-81. PubMed ID: 17028170
[TBL] [Abstract][Full Text] [Related]
8. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate.
Biolo A; Greferath R; Siwik DA; Qin F; Valsky E; Fylaktakidou KC; Pothukanuri S; Duarte CD; Schwarz RP; Lehn JM; Nicolau C; Colucci WS
Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1926-9. PubMed ID: 19204295
[TBL] [Abstract][Full Text] [Related]
9. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.
El Hafny-Rahbi B; Brodaczewska K; Collet G; Majewska A; Klimkiewicz K; Delalande A; Grillon C; Kieda C
J Cell Mol Med; 2021 Apr; 25(7):3284-3299. PubMed ID: 33624446
[TBL] [Abstract][Full Text] [Related]
10. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
[TBL] [Abstract][Full Text] [Related]
11. myo-Inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane.
Duarte CD; Greferath R; Nicolau C; Lehn JM
Chembiochem; 2010 Dec; 11(18):2543-8. PubMed ID: 21086482
[TBL] [Abstract][Full Text] [Related]
12. ITPP Treatment of RG2 Glioblastoma in a Rat Model.
Förnvik K; Zolfaghari S; Salford LG; Redebrandt HN
Anticancer Res; 2016 Nov; 36(11):5751-5755. PubMed ID: 27793896
[TBL] [Abstract][Full Text] [Related]
13. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.
Derbal-Wolfrom L; Pencreach E; Saandi T; Aprahamian M; Martin E; Greferath R; Tufa E; Choquet P; Lehn JM; Nicolau C; Duluc I; Freund JN
Oncogene; 2013 Sep; 32(36):4313-8. PubMed ID: 23045284
[TBL] [Abstract][Full Text] [Related]
14. Right ventricular myocardial oxygen tension is reduced in monocrotaline-induced pulmonary hypertension in the rat and restored by myo-inositol trispyrophosphate.
Oknińska M; Zambrowska Z; Zajda K; Paterek A; Brodaczewska K; Mackiewicz U; Szczylik C; Torbicki A; Kieda C; Mączewski M
Sci Rep; 2021 Sep; 11(1):18002. PubMed ID: 34504231
[TBL] [Abstract][Full Text] [Related]
15. Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphates.
Grzymajlo K; El Hafny-Rahbi B; Kieda C
J Cell Mol Med; 2023 Mar; 27(6):879-890. PubMed ID: 36852461
[TBL] [Abstract][Full Text] [Related]
16. Tissue pO2 of orthotopic 9L and C6 gliomas and tumor-specific response to radiotherapy and hyperoxygenation.
Khan N; Li H; Hou H; Lariviere JP; Gladstone DJ; Demidenko E; Swartz HM
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):878-85. PubMed ID: 19136221
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma.
Sihn G; Walter T; Klein JC; Queguiner I; Iwao H; Nicolau C; Lehn JM; Corvol P; Gasc JM
FEBS Lett; 2007 Mar; 581(5):962-6. PubMed ID: 17316624
[TBL] [Abstract][Full Text] [Related]
18. Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes.
Görgens C; Guddat S; Schänzer W; Thevis M
Drug Test Anal; 2014; 6(11-12):1102-7. PubMed ID: 25070041
[TBL] [Abstract][Full Text] [Related]
19. Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice.
Iyengar S; Schwartz D
Anticancer Res; 2017 Mar; 37(3):1121-1125. PubMed ID: 28314273
[TBL] [Abstract][Full Text] [Related]
20. Repeated assessment of orthotopic glioma pO(2) by multi-site EPR oximetry: a technique with the potential to guide therapeutic optimization by repeated measurements of oxygen.
Khan N; Mupparaju S; Hou H; Williams BB; Swartz H
J Neurosci Methods; 2012 Feb; 204(1):111-117. PubMed ID: 22079559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
